Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors
Condition(s):Malignant Solid TumoursLast Updated:October 4, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):Malignant Solid TumoursLast Updated:October 4, 2022Recruiting
Condition(s):MelanomaLast Updated:January 25, 2024Not yet recruiting
Condition(s):Advanced Hepatocellular CarcinomaLast Updated:January 18, 2023Withdrawn
Condition(s):Neuroblastoma; Refractory Neuroblastoma; Relapsed NeuroblastomaLast Updated:November 24, 2023Recruiting
Condition(s):Non-Hodgkin’s Lymphoma (NHL); Peripheral T Cell Lymphoma (PTCL)Last Updated:January 6, 2021Unknown status
Condition(s):Solid TumorLast Updated:November 29, 2023Not yet recruiting
Condition(s):Lymphoma, Follicular; Lymphoma, Mantle-Cell; Marginal Zone Lymphoma; Primary Mediastinal B-cell Lymphoma; Diffuse Large B Cell Lymphoma; Lymphoma, Non-HodgkinLast Updated:June 9, 2022Enrolling by invitation
Condition(s):Acute Myeloid LeukemiaLast Updated:January 12, 2023Recruiting
Condition(s):Cancer; Malignancy; Refractory Cancer; Relapsed CancerLast Updated:March 31, 2022Unknown status
Condition(s):Colorectal Cancer; Triple Negative Breast Cancer; Sarcoma; Nasopharyngeal Carcinoma; Prostate Cancer; Gastric CancerLast Updated:September 27, 2019Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.